Trinity's latest blood testing technology to provide precise treatment for prostate cancer patients

Release date: 2017-06-22

We are one step closer to precision medicine for prostate cancer. Researchers have created a trinity blood test that they claim can predict prostate cancer or response to PARP inhibitors, how drugs affect survival rates, and how likely they are to develop resistance.

The co-author of the study, Professor Johann de Bono from the British Cancer Institute and the Royal Marsden NHS Trust, and colleagues published their latest research in the journal Cancer Discovery.

Prostate cancer is the most common cancer in men in the United States, second only to skin cancer.

According to the American Cancer Society, there are approximately 161,360 new cases of prostate cancer in the United States this year, and more than 26,000 people will die as a result.

Genetic mutations account for about 5-10% of all prostate cancer cases. A small number of genetic cases are caused by genetic mutations that often help repair cellular DNA damage, such as the BRCA1 and BRCA2 genes.

For patients with advanced prostate cancer caused by genetic mutations, studies have shown that a class of drugs called PARP inhibitors can effectively kill prostate cancer cells.

Professor de Bono and his research team pointed out that although some patients with prostate cancer respond well to these drugs, some patients with prostate cancer have stopped responding to drugs or becoming resistant to drugs in the early stages of treatment. However, their latest study may be better able to determine which prostate cancer patients are more likely to respond well to PARP inhibitors.

Exploring cancer DNA in circulating blood

The researchers analyzed cancer DNA levels in the blood circulation of 49 elderly patients with advanced prostate cancer , 16 of which responded to a PARP inhibitor treatment called olaparib.

Among male patients with prostate cancer who responded to the drug, the team found that after 8 weeks of treatment, the median cancer DNA in circulating blood decreased by 49.6%. However, after 8 weeks of treatment in men with prostate cancer who did not respond to olaparib , the median cancer DNA in circulating blood increased by 2.1%.

The results of this study show that cancer DNA levels in circulating blood can help doctors determine which prostate cancer patients are most likely to respond to PARP inhibitor treatment. If the response rate is low, prostate cancer patients can decide to switch to another treatment within a few weeks.

The researchers found that they could also determine the survival rate of patients with prostate cancer after receiving olaparib. The average life expectancy of patients with decreased circulating DNA in circulating blood was extended by 7 months compared with those of prostate cancer patients who received high levels of cancer DNA in circulating blood after 8 weeks of treatment with olaparib .

Finally, the researchers identified biomarkers that could help predict the likelihood of resistance to olaparib in patients. Among patients who stopped responding to the drug, the researchers found that their cancer cells had undergone genetic variability, offsetting mutations in DNA repair genes that previously made them susceptible to olaparib .

"A new era of precision medicine"

Although this latest blood test technology requires more in-depth research in a larger sample of patients, the researchers believe that this latest study paves the way for "starting a new era of precision medicine for prostate cancer."

Professor de Bono said: "Through this study, we were able to develop a powerful Trinity detection technology that will help doctors choose treatments in the future, test whether medications are effective, and monitor cancer for long-term."

Source: Noble

N Isopropylbenzylamine

ynephrine (or oxedrine) is a drug commonly used for weight loss. While its effectiveness is widely debated, synephrine has gained si

ynephrine (or oxedrine) is a drug commonly used for weight loss. While its effectiveness is widely debated, synephrine has gained significant popularity as an alternative to, a related substance which has been made illegal or restricted in many countries due to health risks and its use as a precursor in the illicit manufacturing.

There is however no occurrence of diverted synephrine for the manufacture of amphetamines, and the naturally occurring synephrine is, due to its phenolic group, unsuitable for such diversion.

Products containing bitter orange or synephrine are suspected of causing adverse cardiovascular reactions. Synephrine is derived primarily from the immature fruit of Citrus aurantium, a relatively small citrus tree, of which several of its more common names include Bitter Orange, Sour Orange, and Zhi shi. Dietary supplements generally supply single oral doses of 3–30 mg, while as a pharmaceutical agent it is given orally or by parenteral injection in 20–100 mg doses as a vasoconstrictor to hypotensive patients.

Our company offers variety of products which can meet your multifarious demands.including API Powder.Pharmaceutical Intermediates.Vitamins Powder.Plant Extracts.Food Additive.Peptide Powder and so on We adhere to the management principles of "quality first, customer first and credit-based" since the establishment of the company and always do our best to satisfy potential needs of our customers. Our company is sincerely willing to cooperate with enterprises from all over the world in order to realize a win-win situation since the trend of economic globalization has developed with anirresistible force.

Describe :

item	Synephrine hydrochloride
CAS No.	5985-28-4
Other Names	N-Isopropylnorsynephrine HCL
MF	C9H14ClNO2
EINECS No.	/
Place of Origin	China
Type	Pharmaceutical Intermediates, Syntheses Material Intermediates
Purity	99%
Brand Name	Vanz
Model Number	Vanz20210420
Application	sport nutrition
Appearance	white powder
Product Name	Synephrine hydrochloride
CAS	5985-28-4
Appearance	white powder
Shelf life	2 Years
Package	25kg/drum
Certificate	ISO9001
Storage	Cool Dried Storage
Test Method	HPLC Test
Payment term	TT.Western Union .Credit Card
Assay	99%min

product name:

gnificant popularity as an alternative to, a related substance which has been made illegal or restricted in many countries due to health risks and its use as a precursor in the illicit manufacturing.

There is however no occurrence of diverted synephrine for the manufacture of amphetamines, and the naturally occurring synephrine is, due to its phenolic group, unsuitable for such diversion.

Products containing bitter orange or synephrine are suspected of causing adverse cardiovascular reactions. Synephrine is derived primarily from the immature fruit of Citrus aurantium, a relatively small citrus tree, of which several of its more common names include Bitter Orange, Sour Orange, and Zhi shi. Dietary supplements generally supply single oral doses of 3–30 mg, while as a pharmaceutical agent it is given orally or by parenteral injection in 20–100 mg doses as a vasoconstrictor to hypotensive patients.

Our company offers variety of products which can meet your multifarious demands.including API Powder.Pharmaceutical Intermediates.Vitamins Powder.Plant Extracts.Food Additive.Peptide Powder and so on We adhere to the management principles of "quality first, customer first and credit-based" since the establishment of the company and always do our best to satisfy potential needs of our customers. Our company is sincerely willing to cooperate with enterprises from all over the world in order to realize a win-win situation since the trend of economic globalization has developed with anirresistible force.

Describe :

N Isopropylbenzylamine,Inositol Powder,Best Inositol Powder,Benzylisopropylamine Cas 102-97-6

Shaanxi YXchuang Biotechnology Co., Ltd , https://www.peptidenootropics.com